William Blair analyst Myles Minter has maintained their bullish stance on XENE stock, giving a Buy rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Myles Minter has given his Buy rating due to a combination of factors including the promising progress of Xenon’s X-TOLE2 trial, which is on track for a significant data release in early 2026. Despite some market volatility and concerns about the timing of the data release, Minter sees this as an overreaction and believes the upcoming results could be a major catalyst for the company.
Minter is optimistic about the potential of azetukalner, which has shown strong efficacy in treating a highly refractory population and continues to demonstrate robust results in long-term studies. Additionally, the diversification of Xenon’s pipeline with the NaV1.7 inhibitor and Kv7 potentiator programs in pain management further strengthens the company’s position. These factors contribute to Minter’s view of Xenon as a leader in the development of new antiseizure medications with significant market potential.
Minter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Alector, and Argenx Se. According to TipRanks, Minter has an average return of 29.1% and a 59.85% success rate on recommended stocks.
In another report released today, Needham also maintained a Buy rating on the stock with a $55.00 price target.